Legal & General Group Plc Cuts Position in Progyny, Inc. (NASDAQ:PGNY)

Legal & General Group Plc reduced its holdings in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) by 7.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 214,552 shares of the company's stock after selling 16,158 shares during the quarter. Legal & General Group Plc owned 0.25% of Progyny worth $3,701,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Leibman Financial Services Inc. lifted its holdings in Progyny by 100.7% in the fourth quarter. Leibman Financial Services Inc. now owns 63,509 shares of the company's stock valued at $1,096,000 after acquiring an additional 31,872 shares during the period. Fort Washington Investment Advisors Inc. OH lifted its holdings in Progyny by 90.1% in the fourth quarter. Fort Washington Investment Advisors Inc. OH now owns 1,467,780 shares of the company's stock valued at $25,319,000 after acquiring an additional 695,740 shares during the period. Clear Harbor Asset Management LLC bought a new position in Progyny in the fourth quarter valued at about $989,000. Barclays PLC lifted its holdings in Progyny by 530.4% in the third quarter. Barclays PLC now owns 706,157 shares of the company's stock valued at $11,835,000 after acquiring an additional 594,140 shares during the period. Finally, Baillie Gifford & Co. lifted its holdings in Progyny by 52.2% in the fourth quarter. Baillie Gifford & Co. now owns 1,332,690 shares of the company's stock valued at $22,989,000 after acquiring an additional 456,853 shares during the period. 94.93% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have weighed in on the company. BTIG Research raised Progyny from a "neutral" rating to a "buy" rating and set a $28.00 target price on the stock in a report on Monday, March 31st. JPMorgan Chase & Co. upped their price target on Progyny from $17.00 to $23.00 and gave the stock a "neutral" rating in a research report on Tuesday, January 28th. Bank of America upped their price target on Progyny from $21.00 to $25.00 and gave the stock a "buy" rating in a research report on Tuesday, February 11th. Finally, Canaccord Genuity Group upped their price target on Progyny from $17.00 to $23.00 and gave the stock a "hold" rating in a research report on Friday, February 28th. Eight equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat, Progyny presently has an average rating of "Hold" and an average target price of $23.64.

Progyny Price Performance

Shares of NASDAQ:PGNY traded down $0.01 during trading on Monday, hitting $22.75. 504,896 shares of the company's stock were exchanged, compared to its average volume of 1,743,182. Progyny, Inc. has a 52-week low of $13.39 and a 52-week high of $33.84. The business's 50-day simple moving average is $21.92 and its 200 day simple moving average is $19.14. The company has a market cap of $1.95 billion, a price-to-earnings ratio of 39.22, a PEG ratio of 2.39 and a beta of 1.33.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.